MYOS Corp. (OTCQB: MYOS) is a development stage company engaged in the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia (age-related loss of muscle mass), cachexia (general physical wasting and malnutrition), and degenerative muscle diseases. The company’s Fortetropin™ (also known as MYO-T12^®) is the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein that inhibits muscle growth and recovery; research suggests that lowering myostatin levels has many health benefits, including increased muscle mass, healthy weight management, improved energy levels, and stimulated muscle healing. For more information, visit the company’s website at www.myoscorp.com